Page 89 - 2021_03-Haematologica-web

Risk-adapted R-EPOCH in DLBCL
References
1. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diag- nosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):116-125.
2. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8(3):288-334.
3. Wasterlid T, Biccler JL, Brown PN, et al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B- cell lymphoma: a Nordic Lymphoma Group population-based study. Ann Oncol. 2018; 29(8):1882-1883.
4.Poeschel V, Held G, Ziepert M, et al. Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B-cell lymphoma treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the FLYER trial of the DSHNHL/GLA. Blood. 2018;132 (Suppl 1):781.
5. Sparano JA, Weller E, Nazeer T, et al. Phase 2 trial of infusional cyclophosphamide, dox- orubicin, and etoposide in patients with poor-prognosis, intermediate-grade non- Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002;100(5):1634-1640.
6. Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non- Hodgkin's lymphoma: evidence for a sched- ule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol. 1993;11(6):1071-1079.
7. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lym- phoma. J Clin Oncol. 1993;11(8):1573-1582.
8. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a phar- macodynamic approach with high efficacy. Blood. 2002;99(8):2685-2693.
9. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodefi- ciency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretro- viral therapy suspension and tumor biology. Blood. 2003;101(12):4653-4659.
10. Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, dox- orubicin, and etoposide plus didanosine and filgrastim in patients with human immun- odeficiency virus-associated non-Hodgkin's lymphoma. J Clin Oncol. 1996;14(11):3026- 3035.
11. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, dox- orubicin, and etoposide in patients with HIV- associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol. 2004;22(8):1491-1500.
12.Spina M, Jaeger U, Sparano JA, et al.
Rituximab plus infusional cyclophos- phamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105(5):1891-1897.
13. Sparano JA. HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol. 2007;19(5):458- 463.
14. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lym- phoma. Blood. 2010;115(15):3008-3016.
15.Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical out- come in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to stan- dardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4): 1244.
17. Barta SK, Joshi J, Mounier N, et al. Central nervous system involvement in AIDS-relat- ed lymphomas. Br J Haematol. 2016;173 (6):857-866.
18. Ngongondo M, Kang M, Umbleja T, et al. Early progression and immune reconstitu- tion inflammatory syndrome during treat- ment of mild-to-moderate Kaposi sarcoma in low-resource settings: incidence, long- term outcomes and effects of early chemotherapy. 17th International Conference on HIV AIDS, Bethesda, MD, USA. October 21-22, 2019.
19.Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369(20):1915-1925.
20. Dunleavy K, Noy A, Abramson JS, et al. Risk-adapted therapy in adults with Burkitt lymphoma: preliminary report of a multi- center prospective phase II study of DA- EPOCH-R. Blood. 2015;126(23):342-342.
21. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV- associat- ed non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-3262.
22. Chadburn A, Chiu A, Lee JY, et al Immunophenotypic analysis of AIDS- relat- ed diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009;27(30):5039- 5048.
23. Dunleavy K, Little RF, Pittaluga S, et al The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense ritux- imab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024.
24. Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large B-
cell lymphoma. N Engl J Med. 2018;378(15):
1396-1407.
25. Mikhaeel NG, Timothy AR, O'Doherty MJ,
Hain S, Maisey MN. 18-FDG-PET as a prog- nostic indicator in the treatment of aggres- sive non-Hodgkin's lymphoma -comparison with CT. Leuk Lymphoma. 2000;39(5- 6):543-553.
26. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomogra- phy with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non- Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.
27. Haioun C, Itti E, Rahmouni A, et al. [18F]flu- oro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lym- phoma: an early prognostic tool for predict- ing patient outcome. Blood. 2005;106(4): 1376-1381.
28. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without ritux- imab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglu- cose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20(3):503-507.
29. Carr R, Fanti S, Paez D, et al. Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med. 2014;55(12):1936-1944.
30. Dabaja BS, Vanderplas AM, Crosby- Thompson AL, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes proj- ect. Cancer. 2015;121(7):1032-1039.
31. Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emis- sion tomography in patients with diffuse large B-cell lymphoma treated with R- CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33(23):2523-2529.
32. Swinnen LJ, Li H, Quon A, et al. Response- adapted therapy for aggressive non- Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015;170(1):56-65.
33. Duhrsen U, Muller S, Hertenstein B, et al. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, ran- domized phase III trial. J Clin Oncol. 2018;36(20):2024-2034.
34. Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130(11):1315-1326.
35.Mhlanga JC, Durand D, Tsai HL, et al. Differentiation of HIV-associated lym- phoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry. Eur J Med Mol Imaging. 2014;41(4):596-604.
haematologica | 2021; 106(3)
735